IM Cannabis Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

IM Cannabis heeft een totaal eigen vermogen van CA$5.5M en een totale schuld van CA$15.1M, wat de schuld-eigenvermogensverhouding op 276.4% brengt. De totale activa en totale passiva bedragen respectievelijk CA$40.2M en CA$34.7M.

Belangrijke informatie

276.4%

Verhouding schuld/eigen vermogen

CA$15.15m

Schuld

Rente dekkingsratio	n/a
Contant	CA$700.00k
Aandelen	CA$5.48m
Totaal verplichtingen	CA$34.74m
Totaal activa	CA$40.22m

Recente financiële gezondheidsupdates

Health Check: How Prudently Does IM Cannabis (CSE:IMCC) Use Debt?

Dec 24

Recent updates

Slammed 28% IM Cannabis Corp. (CSE:IMCC) Screens Well Here But There Might Be A Catch

Sep 13

Don't Ignore The Fact That This Insider Just Sold Some Shares In IM Cannabis Corp. (CSE:IMCC)

Feb 05

What Percentage Of IM Cannabis Corp. (CSE:IMCC) Shares Do Insiders Own?

Jan 08

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CA$22.9M ) van IMCC } dekken niet de korte termijn passiva ( CA$33.4M ).

Langlopende schulden: De kortetermijnactiva IMCC ( CA$22.9M ) overtreffen de langetermijnschulden ( CA$1.3M ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 263.6% ) IMCC wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van IMCC is de afgelopen 5 jaar gestegen van 0% naar 276.4%.

Balans

Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: Terwijl het verlieslatende IMCC voldoende cash runway heeft voor meer dan 3 jaar, als het zijn huidige positieve vrije kasstroom-niveau behoudt.

Voorspelling contante baan: IMCC is verlieslatend, maar heeft voldoende kasmiddelen voor meer dan 3 jaar, zelfs bij een positieve vrije kasstroom die met 5.1 % per jaar krimpt.

IM Cannabis Balans Gezondheid

Financiële gezondheid criteriumcontroles 3/6

Belangrijke informatie

Recente financiële gezondheidsupdates

IM Cannabis Receives NASDAQ Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement

IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

Health Check: How Prudently Does IM Cannabis (CSE:IMCC) Use Debt?

Recent updates

IM Cannabis Corp. announced that it expects to receive $1.613 million in funding

Slammed 28% IM Cannabis Corp. (CSE:IMCC) Screens Well Here But There Might Be A Catch

IM Cannabis Corp. Appoints Shmulik Arbel to Board of Directors

Price target decreased by 72% to CA$20.70

A Piece Of The Puzzle Missing From IM Cannabis Corp.'s (CSE:IMCC) Share Price

IM Cannabis Corp. announced that it has received CAD 2.091977 million in funding

First quarter 2024 earnings released: CA$0.42 loss per share (vs CA$0.027 profit in 1Q 2023)

IM Cannabis Corp. to Report Q1, 2024 Results on May 08, 2024

Full year 2023 earnings released: CA$0.74 loss per share (vs CA$3.14 loss in FY 2022)

New major risk - Revenue and earnings growth

IM Cannabis Corp. to Report Fiscal Year 2023 Results on Mar 28, 2024

Kadimastem Ltd (TASE:KDST) entered into a non-binding term sheet to acquire IM Cannabis Corp. (CNSX:IMCC) in reverse merger transaction.

IM Cannabis Announces Receipt of Court Action

Third quarter 2023 earnings released: CA$0.16 loss per share (vs CA$0.59 loss in 3Q 2022)

New major risk - Revenue and earnings growth

IM Cannabis Corp. to Report Q3, 2023 Results on Nov 13, 2023

IM Cannabis Corp. Announces Executive Changes

IM Cannabis Corp., Annual General Meeting, Dec 06, 2023

IM Cannabis Corp. Announces Departure of Itay Vago as CFO

New major risk - Market cap size

Second quarter 2023 earnings released: CA$0.26 loss per share (vs CA$0.49 loss in 2Q 2022)

IM Cannabis Corp. to Report Q2, 2023 Results on Aug 14, 2023

Potential Upside For IM Cannabis Corp. (CSE:IMCC) Not Without Risk

New major risk - Financial position

IM Cannabis Receives NASDAQ Notification of Regaining Compliance with Nasdaq's Minimum Bid Price Requirement

New major risk - Share price stability

IM Cannabis Corp. to Report Q1, 2023 Results on May 15, 2023

Full year 2022 earnings released: CA$3.13 loss per share (vs CA$3.07 loss in FY 2021)

Price target decreased by 72% to CA$3.45

IM Cannabis Corp. Commences Exit of Canadian Cannabis Market to Focus its Resources on Pursuing Growth Opportunities in Israel, Germany and Europe

IM Cannabis Corp. to Report Q3, 2022 Results on Nov 14, 2022

High number of new directors

High number of new directors

CEO & Director recently bought CA$157k worth of stock

Executive Chairman recently bought CA$105k worth of stock

IM Cannabis Corp. Announces Board Changes

IM Cannabis Corp. announced that it expects to receive $5 million in funding

Second quarter 2022 earnings released: CA$0.27 loss per share (vs CA$0.10 loss in 2Q 2021)

IM Cannabis Corp., Annual General Meeting, Oct 20, 2022

IM Cannabis Corp. to Report Q2, 2022 Results on Aug 15, 2022

IM Cannabis Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency

First quarter 2022 earnings released: CA$0.14 loss per share (vs CA$0.11 profit in 1Q 2021)

IM Cannabis Corp. Provides Preliminary Unaudited Revenue Guidance for the Second Quarter 2022

IM Cannabis Corp. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to CA$6.00

High number of new and inexperienced directors

CEO & Director recently bought CA$423k worth of stock

Full year 2021 earnings released: CA$0.31 loss per share (vs CA$0.74 loss in FY 2020)

Health Check: How Prudently Does IM Cannabis (CSE:IMCC) Use Debt?

IM Cannabis Corp. Provides Earnings Guidance for Fourth Quarter of 2021 and Full Year 2022

Price target decreased to CA$7.63

Third quarter 2021 earnings released: CA$0.06 loss per share (vs CA$0.017 profit in 3Q 2020)

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Director Marc Lustig has joined 5th company board

Insider recently sold CA$76k worth of stock

Second quarter 2021 earnings released: CA$0.10 loss per share (vs CA$0.25 loss in 2Q 2020)

Price target decreased to CA$9.50

IM Cannabis Corp. Unveils Proprietary Data from A Clinical Survey Evaluating Medicinal Cannabis Therapy

First quarter 2021 earnings released: EPS CA$0.11 (vs CA$0.011 loss in 1Q 2020)

IM Cannabis Corp. Provides Earnings Guidance for the Second Quarter of 2021

Full year 2020 earnings released: CA$0.74 loss per share (vs CA$0.23 loss in FY 2019)

IM Cannabis Corp. Provides Preliminary Earnings Guidance for the First Quarter and Second Quarter of 2021

IM Cannabis Corp. (CNSX:IMCC) completed the acquisition of Trichome Financial Corp. (CNSX:TFC) from Cresco Labs Inc., Opaskawayak Cree Nation and others.

IM Cannabis Corp. Announces Board Changes

IM Cannabis Corp. to Bring Canadian Premium Indoor High-THC Medical Cannabis to Israel with Imports from GTEC Holdings Ltd

New 90-day high: CA$12.00

IM Cannabis Corp. Announces Board Changes

Director recently sold CA$120k worth of stock

Director recently sold CA$50k worth of stock

Don't Ignore The Fact That This Insider Just Sold Some Shares In IM Cannabis Corp. (CSE:IMCC)

What Percentage Of IM Cannabis Corp. (CSE:IMCC) Shares Do Insiders Own?